Samsung Biologics Co.,Ltd.
207940
Rangering i aksjer
#496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Aksjekurs
$1,028.49
Markedsverdi
$47.88B
Endring (1 dag)
-3.67%
Endring (1 år)
-18.37%
Land
KR
Handel Samsung Biologics Co.,Ltd. (207940)
Kategori
Healthcare
Inntekter for Samsung Biologics Co.,Ltd. (207940)
Inntekter i Sep 2026 TTM: $3.30B
Ifølge de nyeste økonomiske rapportene til Samsung Biologics Co.,Ltd. er selskapets nåværende inntekter (TTM) $3.30B. I 2024 hadde selskapet inntekter på $2.38B en nedgang sammenlignet med inntektene i 2023, som var $2.85B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Samsung Biologics Co.,Ltd. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $3.30B | 4.55% |
| 2025 | $3.15B | 32.61% |
| 2024 | $2.38B | -16.65% |
| 2023 | $2.85B | 20.00% |
| 2022 | $2.38B | 80.33% |
| 2021 | $1.32B | 22.93% |
| 2020 | $1.07B | 76.59% |
| 2019 | $607.57M | 26.26% |
| 2018 | $481.19M | 10.37% |
| 2017 | $435.96M | 78.42% |
| 2016 | $244.35M | 214.60% |
| 2015 | $77.67M | -19.17% |
| 2014 | $96.09M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 282.80% |
US
|
|
| $2.23B | -32.44% |
US
|
|
| $15.74B | 377.41% |
AU
|
|
| $10.11B | 206.59% |
BE
|
|
| $6.02B | 82.58% |
NL
|
